A Phase II Study of docetaxel, estramustine and low dose hydrocortisone in hormone refractory prostate cancer
A Phase II Study of docetaxel, estramustine and low dose hydrocortisone in hormone refractory prostate cancer. Proc Am Soc Clin Onc. 1999; 18:295.